Free Trial
NASDAQ:CHFS

Nuwellis (CHFS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.24
$0.27
50-Day Range
$3.53
$6.02
52-Week Range
$4.86
$37.50
Volume
1.41 million shs
Average Volume
467,323 shs
Market Capitalization
$1.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CHFS stock logo

About Nuwellis Stock (NASDAQ:CHFS)

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

CHFS Stock News Headlines

Why Is Nuwellis (NUWE) Stock Down Today?
BetterHelp Online Therapy Review 2023
Form 424B4 Nuwellis, Inc. - StreetInsider.com
See More Headlines
Receive CHFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/01/2021
Today
5/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical Equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:CHFS
Previous Symbol
NASDAQ:SSH
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

Net Income
$-18,110,000.00
Net Margins
-254.26%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.51 million
Book Value
$12.79 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.48 million
Optionable
Not Optionable
Beta
1.55
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Nestor Jaramillo
    President, Chief Executive Officer, CFO & Director
  • Vitaliy Epshteyn
    Senior Vice President-Operations & Engineering
  • David Lerner
    Chief Technology Officer
  • Thomas P. Lynch
    Secretary, Chief Legal & Compliance Officer
  • Laurent Duhoux
    Vice President-International Business Development

CHFS Stock Analysis - Frequently Asked Questions

How were Nuwellis' earnings last quarter?

Nuwellis, Inc. (NASDAQ:CHFS) posted its quarterly earnings results on Monday, March, 1st. The company reported ($1.57) earnings per share for the quarter, beating the consensus estimate of ($1.91) by $0.34. The company earned $2.04 million during the quarter. Nuwellis had a negative net margin of 254.26% and a negative trailing twelve-month return on equity of 173.61%.

When did Nuwellis' stock split?

Nuwellis's stock reverse split on the morning of Friday, October 13th 2017. The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 12th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Nuwellis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nuwellis investors own include Biocept (BIOC), Immutep (IMMP), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Zosano Pharma (ZSAN), Avinger (AVGR), Co-Diagnostics (CODX), iBio (IBIO), Inovio Pharmaceuticals (INO) and Onconova Therapeutics (ONTX).

This page (NASDAQ:CHFS) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners